Infervision

Infervision Medical Technology Co., Ltd. was founded in 2016, focusing on the AI medical field with the vision of "AI Improving Life and Health," and is committed to becoming an international leading brand in the full hospital-level AI sector. The company adopts a "horizontal and vertical" and "international" strategic layout to build a three-dimensional product line. Horizontally, it fully covers multiple disease areas such as cancer, infectious diseases, cardiovascular diseases, cerebrovascular diseases, and trauma; vertically, it follows the patient's diagnosis and treatment process, covering disease screening and diagnosis, disease intervention and treatment, patient health management, and medical research, providing advanced integrated smart healthcare services for governments, medical institutions, doctors, and patients. The company’s products have obtained market access approvals from China’s NMPA, the U.S. FDA, the EU CE, the UK MHRA, and Japan’s PMDA, with coverage in over 1,000 medical institutions across 25 countries worldwide.